Assessment of the effect of erdafitinib on cardiac safety: analysis of ECGs and exposure-QTc in patients with advanced or refractory solid tumors.
Saved in:
| Title: | Assessment of the effect of erdafitinib on cardiac safety: analysis of ECGs and exposure-QTc in patients with advanced or refractory solid tumors. |
|---|---|
| Authors: | Valade E; Janssen Research and Development, Turnhoutseweg 30, 2340, Beerse, Antwerp, Belgium., Dosne AG; Janssen Research and Development, Turnhoutseweg 30, 2340, Beerse, Antwerp, Belgium. adosne@its.jnj.com., Xie H; Janssen Research and Development, Spring House, PA, USA., Kleiman R; eResearch Technology Inc. (ERT), Philadelphia, PA, USA., Li LY; Janssen Research and Development, Spring House, PA, USA., Perez-Ruixo JJ; Janssen Research and Development, Turnhoutseweg 30, 2340, Beerse, Antwerp, Belgium., Ouellet D; Janssen Research and Development, Spring House, PA, USA. |
| Source: | Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2019 Sep; Vol. 84 (3), pp. 621-633. Date of Electronic Publication: 2019 Jul 06. |
| Publication Type: | Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Springer Verlag Country of Publication: Germany NLM ID: 7806519 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0843 (Electronic) Linking ISSN: 03445704 NLM ISO Abbreviation: Cancer Chemother Pharmacol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1432-0843 |
|---|---|
| DOI: | 10.1007/s00280-019-03896-1 |
